Nasus Pharma Ltd. announced positive interim results from its Phase 2 clinical study of NS002, an investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis. According to the company, interim data showed that NS002 achieved faster absorption, higher peak concentrations, and greater early epinephrine exposure compared to the intramuscular EpiPen® autoinjector. The study reported that 91% of participants reached the 100 pg/ml plasma threshold at 5 minutes with NS002, compared to 67% with EpiPen®. NS002 was well-tolerated, with no serious adverse events reported, and demonstrated a pharmacodynamic response comparable to EpiPen®. Full Phase 2 results are expected by the end of the first quarter of 2026, with a pivotal clinical study planned to begin in the fourth quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001160114-en) on January 20, 2026, and is solely responsible for the information contained therein.